Trump Will Unveil New Medicaid Drug Pricing Rules
The policy shift will impact state-run healthcare programs, potentially altering drug procurement costs for providers.
Updated on Sept. 18, 2026 in Economic Policy
Live Poll
Should the federal government regulate prescription drug prices to reduce costs for patients?
President Trump is set to announce changes to Medicaid drug pricing, a policy expected to grant state programs access to most favored nation pricing for certain medications. The announcement will occur on September 19, 2026, and is slated to affect programs across all 50 states.
Why it matters
The shift toward most favored nation pricing aims to address drug affordability concerns as political focus intensifies ahead of midterm elections. For operators in the healthcare sector, the change represents a significant adjustment to how drugs are procured and reimbursed within the Medicaid framework.
The new policy will apply to Medicaid programs across all 50 states. The administration is implementing this change to secure most favored nation pricing for select drugs, though the full scope of products affected remains unknown.
The players
Donald Trump
The current President of the United States who is exercising executive authority over national drug pricing policy.
The details
The policy change is designed to leverage the purchasing power of Medicaid to secure lower prescription drug costs. By adopting a most favored nation model, the administration intends to align state Medicaid pricing with the lowest prices paid by other entities. This shift requires healthcare providers and state agencies to recalibrate their procurement strategies to account for the new price benchmarks.
Timeline
September 19, 2026, at 2:30 p.m. EDT.
Market Landscape
This policy follows the established pattern of the Most Favored Nation model for drug pricing in the U.S. By applying this framework to Medicaid, the administration is extending a mechanism previously debated in federal policy to state-administered healthcare programs.
Operators in the pharmacy and healthcare sectors should prepare for potential adjustments in reimbursement rates and drug procurement costs. Monitor the official rollout for specific formulary changes that will dictate how Medicaid-covered drugs are priced and distributed.
The takeaway
The move to extend most favored nation pricing to Medicaid highlights a push for lower procurement costs in state healthcare markets. Businesses should monitor upcoming regulatory filings for the specific list of affected drugs and the mandatory effective date for these new pricing requirements.
Further reading
For broader context on federal healthcare regulation, see Economic Policy.
Live Poll
Should the federal government regulate prescription drug prices to reduce costs for patients?
